Key takeaways
Biologics, drugs, and cell and gene therapies are pushing more product into the pharma cold chain than the system was built to handle.
Labor is the quiet constraint: skilled cold chain staff are scarce, and turnover in cold storage runs far above other industries.
Capacity is growing lane by lane, not evenly, so a route that worked last quarter may not work today.
Shippers who qualify packaging per lane, plan backups, and keep real-time visibility absorb the pressure best.
Every cold chain shipment is a bet that dozens of handoffs will go right. Right now, the odds are getting harder to manage. More temperature-sensitive drugs are moving, fewer experienced people are handling them, and the lanes they travel are changing faster than most shipping plans.
For operations and supply chain teams, the pharma cold chain is no longer a background function. It is where product value, patient access, and compliance risk meet. Here is what is putting it under strain and what shippers can do about it.
Demand: More Therapies Need the Cold Chain
Temperature-sensitive products are growing faster than the rest of the pharma portfolio. A report from the HDA Research Foundation found that cold chain products outpaced non-cold chain therapies by 21% over a six-year period (Pharmaceutical Commerce).
GLP-1 drugs add a second wave. A Gallup poll found that 11% of Americans now take GLP-1 medications for weight loss, up from 3% two years earlier (CNBC). Most injectable versions require refrigerated storage and transport, and Pharmaceutical Commerce reports that use has roughly quadrupled in that time.
Biologics and cell and gene therapies raise the stakes further, because each has narrower temperature windows and higher per-dose value. The cost of getting it wrong is already large: temperature excursions are estimated to destroy about $35 billion in pharma product each year (Pharmaceutical Commerce).
Labor: The Skills Gap Behind Every Handoff
More volume means more hands, and those hands are hard to find. A Descartes survey of 1,000 supply chain leaders found that more than three-quarters faced significant workforce shortages, and 37% of them rated the shortages high to extreme (Frozen and Refrigerated Buyer).
Cold environments make it worse. Older Global Cold Chain Alliance figures put turnover in North American cold storage near 33%, nearly nine times the average for all industries (Frozen and Refrigerated Buyer). Operators also report that certified maintenance technicians are among the hardest roles to fill.
Pharma adds a skills layer on top of headcount. Industry speakers at a recent pharma logistics conference described the scarcest skill as seeing the whole chain at once (Pharmaceutical Commerce). That covers packaging, handoffs, data, and provider capabilities. When that view is missing, the result is often an unplanned temperature excursion or lost product.
The HDA report recommended a sector-wide cold chain workforce certification program. Until something like it exists, shippers need to treat provider expertise as a selection criterion, not an assumption.
Capacity: Lanes and Lift Are Not Evenly Spread
There is no single number for pharma cold chain capacity, because capacity is local. It depends on the lane, the airport, the facility, and the week.
Carriers are responding with targeted investment. One major air carrier recently added six dedicated healthcare corridors linking Europe and North America to Asia, using freighters with three separate temperature compartments (Pharmaceutical Commerce). Large parcel carriers have also committed tens of millions of dollars to temperature-controlled facilities (CNBC).
New corridors help the shippers who can use them. For everyone else, they change the map. A new dedicated lane alters transit time and thermal exposure, so packaging that was qualified for the old route may no longer fit the new one.
What Shippers Can Do Now
Pressure on demand, labor, and capacity will not ease soon, but its effects are manageable with a few disciplined practices.
Qualify packaging for each lane and duration. A box validated for 48 hours on one route is not safe for 72 hours on another. Review passive and active options against actual transit times, including realistic delays, and see how cold chain packaging choices compare.
Plan a backup for every critical lane. Know in advance what you will do if a flight is cancelled or a hub is congested. Pre-approved alternatives, such as same-day or next flight out service, turn a crisis into a routine reroute.
Close visibility gaps. Continuous monitoring and real-time tracking let teams act while product is still recoverable, instead of discovering a problem at delivery.
Document handoffs and train for exceptions. When turnover is high, written procedures and clear escalation paths keep quality steady as people change. Ask every provider how it trains staff and handles delays.
Build GDP and regulatory readiness into the plan. Staffing gaps are where documentation errors start. Align procedures with WHO GDP principles so audits are not a surprise.
How Mercury Supports Pharma Cold Chain Programs
Mercury is a veteran-owned healthcare and life sciences logistics specialist. Our team manages specialty cold chain shipments with validated packaging, continuous temperature monitoring, and 24/7 operational support.
When a lane fails or a deadline tightens, Next Flight Out and same-day courier service give teams a fast, controlled backup.
We support pharmaceutical and clinical trial shippers who cannot afford a gap in the chain.
Contact Mercury to build a pharma cold chain plan that holds up under pressure.
Start shipping today!
Start your shipment now — no login required. Fast, secure, and guided by experts.
